oracea articles ↓

 

Oracea approved for much of Europe

In the news this week is an announcement that Oracea is on its way to being approved for sale in Germany, UK, Italy, Austria, Ireland, Sweden, Finland, Luxembourg and The Netherlands. European Regulatory Authority (EMEA) Recommends Granting Of Marketing Authorization For MediGene’s Drug Oracea MediGene AG announced that the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) has concluded …

 

Galderma buys CollaGenex for $420m

Collagenex is set to become a subsidiary of the much bigger Galderma, after CollaGenex agreed to a merger. So 2 of the biggest pharmaceutical companies involved with make rosacea treatments are to become the same company. Galderma has long been associated with rosacea treatment, and is best known for the metronidazole based topicals metrogel, metrocream and metrolotion. CollaGenex has become known in recent years …

 

oral repeat prescriptions more popular than topicals

This paper comes up with the seemingly simple and innocuous result that rosacea sufferers are more likely to fill prescription repeats for oral treatments compared to topicals. This lead to the suggestion by Collagenex that sufferers are generally more satisfied with the effects of oral treatments. In recent press release they further suggested that this was a reason that the market for Oracea was large …

 

100mg doxycycline no better than oracea

Collagenex is reporting today that Oracea is equally effective as 100mg of doxycycline. This latest press release is a culmination of a trial that we have reported previously - oracea plus metrogel, better than 100mg doxycycline plus metrogel ? and also a 2007 SkinMed paper; maximum effective dose of doxycycline is 40mg a day. The main point of the trial was …

 

get ready for ocular oracea

Thanks for the tip from Ben. A clinical trial listed for treating both facial and ocular rosacea with Oracea suggests that Oracea might soon be marketed directly as an ocular rosacea treatment. This phase 2 trial’s purpose is to determine the safety and efficacy of sub-antimicrobial dose doxycycline in the treatment of patients who have both blepharitis and facial rosacea. The trial …